Burosumab (new indication, 50 M € limit exceeded: FGF23-related hypophosphatemia in tumor-induced osteomalacia)

Subject:

• Active Sustance: Burosumab
• Name: Crysvita®
• Therapeutic area: Hypophosphatemia
• Pharmaceutical company: Kyowa Kirin GmbH

Time table:

• Start: 01.09.2022
• Final decision by G-BA: 16.02.2023

Final decision:

• No additional benefit proved